Disease | Author(s) | Medication | No. of patients |
Adult Still’s disease | Huffstutter and Sienknechet247 | Infliximab | 2 |
Kraetsch et al248 | Infliximab | 6 | |
Weinblatt et al149 | Etanercept | 12 | |
Fernandez-Nibro249 | Etanercept | 3 | |
Amyloidosis | Elkayam et al250 | Infliximab | 1 |
Gottenberg et al251 | Etanercept/infliximab | 15 | |
Ortiz-Santamaria et al252 | Infliximab | 6 | |
Tomero et al253 | Infliximab | 12 | |
Kallinick et al525 | Etanercept | 1 | |
Ravindran et al526 | Etanercept | 1 | |
Smith et al254 | Etanercept | 1 | |
Aphthous stomatitis | Robinson and Guitart255 | Etanercept | 1 |
Vujevich and Zirwas256 | Adalimumab | 1 | |
Atzini et al257 | Etanercept | 1 | |
Back pain (incl sciatica) | Sakellariou et al258 | Infliximab | 1 |
Genevay et al259 | Etanercept | 10 | |
Behçet’s disease | Estrach et al260 | Infliximab/adalimumab | 7 |
Gulli et al261 | Infliximab | 1 | |
Hassard et al262 | Infliximab | 1 | |
Licata et al263 | Infliximab | 1 | |
Melikoghu et al264 | Etanercept | 20 | |
Morillas et al265 | Adalimumab/etanercept | ||
Rosenbaum et al266 | Anti-TNF | 1 | |
Saulsbury and Mann267 | Infliximab | 1 | |
Sangle et al268 | Infliximab | 1 | |
Sfikakis et al269 | Infliximab | 5 | |
Sfikakis270 | Infliximab | 11 | |
Ribi et al271 | Infliximab | 1 | |
Sweiss et al272 | Infliximab | 3 | |
Van Laar et at273 | Adalimumab | 6 | |
Bronchiolitis | Cortot et al274 | Etanercept | 1 |
Cirrhosis and alcoholic hepatitis | Naveau et al176 | Infliximab | 36 |
Spahr et al275 | Infliximab | 20 | |
Wendling et al182 | Infliximab | 1 | |
Menon et al276 | Etanercept | 13 | |
Cutaneous T cell lymphoma | Tsimberidou et al277 | Etanercept | 13 |
Dermatitis, hidradenitis, miscellaneous | Bongartz et al158 | Infliximab | 1 |
Cortis et al278 | Etanercept | 1 | |
Cummins et al279 | Etanercept | 1 | |
Massarotti and Sobell280 | Etanercept | 1 | |
Zeichner et al281 | Adalimumab | 1 | |
Csusak et al280 | Etanercept | 6 | |
Jurgens-Meyer et al | Etanercept | 1 | |
Dermatomyositis | Hengstman et al282 | Infliximab | 2 |
Miller et al283 | Etanercept | 10 | |
Sprott et al284 | Etanercept | 1 | |
Nzeusseu et al285 | Infliximab | 1 | |
Saadeyh286 | Etanercept | 4 | |
Norman et al287 | Etanercept | 2 | |
Erythema nodosum refractory chronic | Ortego-Centeno et al288 | Adalimumab | 1 |
Familial Mediterranean fever | Takada et al289 | Etanercept | 2 |
Ozgocmen et al290 | Etanercept | 1 | |
Felty’s syndrome | Ghavami et al291 | Etanercept | 1 |
Giant cell arteritis | Andonopoulos et al292 | Infliximab | 2 |
Cantini et al293 | Infliximab | 4 | |
Tan et al294 | Etanercept | 1 | |
Ahmed et al295 | 1 | ||
Graft vs host disease (acute) | Wolff et al296 | Etanercept | 21 |
Uberti et al297 | Etanercept | 20 | |
Kennedy et al298 | Etanercept | 20 | |
Chiang et al299 | Etanercept | 8 | |
Pavletic et al300 | Etanercept | 4 | |
Andolina301 | Etanercept | 1 | |
Graves ophthalmopathy | Paridiena et al302 | Etanercept | 10 |
Hepatitis C | Cacoub et al172 | Interferon alfa | 27 |
McMinn et al303 | Etanercept | 3 | |
Peterson et al304 | Infliximab/etanercept | 24 | |
Pritchard 305 | Etanercept | 1 | |
Ince et al127, FF 29 174 | Etanercept | 12 | |
Moreno et al306 | Etanercept | 5 | |
Allen et al307 | Etanercept | 2 | |
Marotte et al308 | Etanercept | 9 | |
Rokhsar309 | Etanercept | 1 | |
Magliocco and Gottlieb264 | Etanercept | 3 | |
HIV | Wallis et al310 | Etanercept | 16 |
Immunodeficiency (common variable) | Smith and Skelton178 | Etanercept | 1 |
Lin et al311 | Etanercept | 1 | |
Capeda et al312 | Etanercept | 7 | |
Inclusion body myositis | Barohn et al313 | Etanercept | 9 (ineffective) |
Singh et al314 | Etanercept | 1 | |
Juvenile-onset HLA-B27-associated severe and refractory heal enthesitis | Olivieri et al315 | Adalimumab | 1 |
Kawasaki’s disease | Weiss et al316 | Infliximab | 1 |
Burns et al317 | Infliximab | 16 | |
Multicentric histiocytosis | Lovelace et al318 | Etanercept | 1 |
Matejicka et al319 | Etanercept | 1 | |
Kovach et al320 | Etanercept | 1 | |
Myelodysplasia | Birnbaum and Gentile321 | Etanercept | 1 |
Deeg et al322 | Etanercept | 14 | |
Rosenfeld et al323 | Etanercept | 19 (ineffective) | |
Raza324 | Etanercept | 26 | |
Maciejewski325 | Etanercept | 16 | |
Periodic fever (children) | Athreya et al326 | Etanercept | 3 |
Pigmented villonodular synovitis | Kroot et al327 | TNF | 1 |
Polymyositis | Hengstman et al282 | Infliximab | 2 |
Sprott et al284 | Etanercept | 1 | |
Adams et al328 | Adalimumab | 2 | |
Polychondritis | Carter (with literature review)329 | Infliximab | 1 |
Ehresman330 | Etanercept | 5 | |
Pyoderma gangrenosum | Fonder et al331 | Adalimumab | 1 |
Heffernan et al332 | Adalimumab | 1 | |
Osteoarthritis (erosine) | Magnano et al333 | Adalimumab | 12 |
SAPHO syndrome | Furst et al1 | TNF | – |
Anker and Coats166 | Infliximab/etanercept | 150 | |
Sweiss et al334 | Infliximab | 3 | |
Callejas-Rubio et al335 | Adalimumab | 1 | |
Korhonen et al336 | Infliximab | 12 | |
Korhonen et al337 | Infliximab | 40 | |
Lam et al338 | Infliximab | 18 | |
Pasternack et al339 | Etanercept | 4 | |
Tobinick and Davoodifar340 | Etanercept | 43 | |
Khanna et al341 | Etanercept | 1 | |
Utz et al342 | Etanercept | 17 | |
Wagner et al343 | Etanercept | 2 | |
Moul et al344 | Adalimumab | 1 | |
Sarcoidosis | Khanna et al343 | Etanercept | 1 |
Utz et al342 | Etanercept | 1 | |
Hefferman et al345 | Adalimumab | 1 | |
Callejas-Rubio335 | Adalimumab | 1 | |
Querfeld et al346 | Etanercept | 1 | |
Sweiss et al272 | Etanercept | 1 | |
Hobbs et al347 | Etanercept | 1 | |
Scleroderma | Ellman et al348 | Etanercept | 8 |
Bosello et al349 | Etanercept | 4 | |
Silicone granulomas | Pasternack et al339 | Etanercept | 2 |
Sjogren’s syndrome | Zandfelt et al350 | Etanercept | 15 (ineffective) |
Sankar et al72 | Etanercept | 14 (ineffective) | |
Pessler et al351 | Etanercept | 1 | |
Still’s disease (include Adult onset) | Fautrel et al352 | Etanercept | 20 (ineffective) |
Stern et al353 | Etanercept | 1 (worsening) | |
Asherson et al354 | Etanercept | 1 | |
Kumari et al355 | Etanercept | 1 | |
Sweet’s syndrome | Gindi et al356 | Etanercept | 1 |
Yamanuchi et al357 | Etanercept | 24 | |
Systemic lupus erythematosus | Aringer et al358 | Infliximab | 6 |
Fantrel et al352 | Etanercept | 1(SCLE) | |
Lurati et al359 | Etanercept | 1 | |
Jackson et al360 | Etanercept | 1(SCLE) | |
Norman et al287 | Etanercept | 1(SCLE) | |
Hernandez-Ibarra et al361 | N/A | – | |
Principi et al362 | Infliximab | 1 | |
Takayasu’s arteritis | Hoffman et al363 | Anti-TNF | 15 |
Della Rossa et al364 | Infliximab | 2 | |
Tato et al365 | Adalimumab | 1 | |
TRAP | Hull et al366 | Etanercept | >50 |
Lamprecht et al367 | Etanercept | 2 | |
Drewe et al368 | Etanercept | 1 | |
Uveitis | Estrach et al260 | Infliximab/adalimumab | 7 |
Joseph et al369 | Infliximab | 5 | |
Smith et al370 | Etanercept | 7 | |
Braun et al371 | Etanercept/Infliximab | 717 (uveitis in AS) | |
Foster et al372 | Etanercept | 20 (ineffective) | |
Biester et al373 | Adalimumab | 18 | |
Foeldvari et al374 | Anti-TNF | 47 | |
Vazquez-Cobain et al375 | Adalimumab | 14 | |
Reiff et al376 | Etanercept | 10 | |
Schmeling and Horneff377 | Etanercept | 20 (ineffective) | |
Guignard et al378 | Adalimumab | 8 | |
Vasculitis (see also Behcet’s, GCA, Takayasu’s, Wegener’s) | Booth et al379 | Infliximab | 32 |
Feinstein and Arroyo380 | Etanercept | 1 | |
Van dan Bijl381 | Infliximab | 11 | |
Saji et al382 | Infliximab | 1 (Kawasaki’s) | |
Sangle et al268 | Infliximab | 1 (Churg-Syrauss) | |
Arbach et al383 | Etanercept/infliximab | 3 | |
Wegener’s granulomatosis | Gause et al384 | Infliximab | 10 |
Sangle et al268 | Infliximab | 3 |
N/A, not available; TNF, tumour necrosis factor; TRAPS, TNF receptor-associated periodic syndrome.